Alessia Bellasame
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alessia Bellasame has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chiara De Simone
Department of Medical, Oral and Biotechnological Sciences, University “G. d’Annunzio” of Chieti-Pescara, 66100 Chieti, Italy
1 shared publication - Fabrizio Di Giuseppe
Center for Advanced Studies and Technologies (CAST), University “G. d’Annunzio” of Chieti-Pescara, Via Luigi Polacchi 13, 66100 Chieti, Italy
1 shared publication - Giorgia Febo
Department of Medical, Oral and Biotechnological Sciences, ‘G. d’Annunzio’ University of Chieti-Pescara, Via Vestini 31, 66100 Chieti, Italy
1 shared publication - Nicola Tupone
Center for Advanced Studies and Technology (CAST), ‘G. D’Annunzio’ University of Chieti-Pescara, Via L Polacchi 13, 66100 Chieti, Italy
1 shared publication - Patricia Giuliani
Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Via dei Vestini 29, 66100 Chieti, Italy
1 shared publication - Patrizia Di Iorio
Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Via dei Vestini 29, 66100 Chieti, Italy
1 shared publication
Latest Publications
- Open Access
- 10 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 9778
Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand?
Like most tumors, glioblastoma multiforme (GBM), the deadliest brain tumor in human adulthood, releases extracellular vesicles (EVs). Their content, reflecting that of the tumor of origin, can be donated to nearby and distant cells which, by acquiring it, become more aggressive. Therefore, the study of EV-transported molecules has become very important. Particular attention has been paid to EV proteins to uncover new GBM biomarkers and potential druggable targets. Proteomic studies have mainly been performed by “bottom-up” mass spectrometry (MS) analysis of EVs isolated by different procedures from conditioned media of cultured GBM cells and biological fluids from GBM patients. Although a great number of dysregulated proteins have been identified, the translation of these findings into clinics remains elusive, probably due to multiple factors, including the lack of standardized procedures for isolation/characterization of EVs and analysis of their proteome. Thus, it is time to change research strategies by adopting, in addition to harmonized EV selection techniques, different MS methods aimed at identifying selected tumoral protein mutations and/or isoforms due to post-translational modifications, which more deeply influence the tumor behavior. Hopefully, these data integrated with those from other “omics” disciplines will lead to the discovery of druggable pathways for novel GBM therapies.
- 10 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 9778
Open AccessProteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand?
Like most tumors, glioblastoma multiforme (GBM), the deadliest brain tumor in human adulthood, releases extracellular vesicles (EVs). Their content, reflecting that of the tumor of origin, can be donated to nearby and distant cells which, by acquiring it, become more aggressive. Therefore, the study of EV-transported molecules has become very important. Particular attention has been paid to EV proteins to uncover new GBM biomarkers and potential druggable targets. Proteomic studies have mainly been performed by “bottom-up” mass spectrometry (MS) analysis of EVs isolated by different procedures from conditioned media of cultured GBM cells and biological fluids from GBM patients. Although a great number of dysregulated proteins have been identified, the translation of these findings into clinics remains elusive, probably due to multiple factors, including the lack of standardized procedures for isolation/characterization of EVs and analysis of their proteome. Thus, it is time to change research strategies by adopting, in addition to harmonized EV selection techniques, different MS methods aimed at identifying selected tumoral protein mutations and/or isoforms due to post-translational modifications, which more deeply influence the tumor behavior. Hopefully, these data integrated with those from other “omics” disciplines will lead to the discovery of druggable pathways for novel GBM therapies.